Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
- Last Action
- 5/12/2023
Actions
- 2023-05-12Referred to the Subcommittee on Health.
- 2023-05-05Referred to the House Committee on Energy and Commerce.
- 2023-05-05Introduced in House
- 2023-05-05Introduced in House
CRS Summary
As of 2023-05-05 (00)
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.
The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.
Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.
Cosponsors (18)
- LLOYD DOGGETT (D-TX)
- Steve Cohen (D-TN)
- ROSA DELAURO (D-CT)
- Jesus Garcia (D-IL)
- Raúl Grijalva (D-AZ)
- Pramila Jayapal (D-WA)
- MARCY KAPTUR (D-OH)
- Ro Khanna (D-CA)
- ELEANOR NORTON (D-DC)
- Chellie Pingree (D-ME)
- Mark Pocan (D-WI)
- JANICE SCHAKOWSKY (D-IL)
- Melanie Stansbury (D-NM)
- Jill Tokuda (D-HI)
- Greg Casar (D-TX)
- Mark Takano (D-CA)
- Seth Magaziner (D-RI)
- Rashida Tlaib (D-MI)
Subjects
- Government information and archives
- Health care costs and insurance
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.